OTCMKTS:ZLDPF FY2025 EPS Estimate Reduced by William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) – Equities research analysts at William Blair reduced their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research report issued on Wednesday, March 12th. William Blair analyst A. Hsieh now anticipates that the company will earn ($2.27) per share for the year, down from their previous estimate of ($2.26). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.19) per share. William Blair also issued estimates for Zealand Pharma A/S’s Q2 2026 earnings at ($0.55) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.18) EPS and FY2027 earnings at ($2.70) EPS.

Separately, Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st.

Zealand Pharma A/S Trading Up 38.9 %

Shares of Zealand Pharma A/S stock opened at $98.91 on Friday. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $97.60 and a 200-day simple moving average of $109.37. The stock has a market cap of $7.02 billion, a price-to-earnings ratio of -41.91 and a beta of 0.92. Zealand Pharma A/S has a 12-month low of $71.20 and a 12-month high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.19. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.